ABBV
vs
S&P 500
ABBV
S&P 500
Over the past 12 months, ABBV has underperformed S&P 500, delivering a return of +8% compared to S&P 500's +26% growth.
Stocks Performance
ABBV vs S&P 500
Performance Gap
ABBV vs S&P 500
Performance By Year
ABBV vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Abbvie Inc
Glance View
AbbVie is a pharmaceutical company that develops and sells prescription medicines. Its business is built around branded drugs for conditions such as immune disorders, cancer, eye disease, and other serious illnesses. It also works on research and development to create new treatments and support its long-term drug portfolio. The company makes money mainly by selling medicines to wholesalers, pharmacies, hospitals, and other healthcare providers, which then reach patients. In some areas it also earns income from licensing and collaboration deals tied to its drug research and development. Because its products are prescription therapies, AbbVie depends on physician adoption, regulatory approval, and patent protection more than on consumer branding. AbbVie’s role in the healthcare system is that of a maker of specialized, high-value medicines rather than a broad medical supplier. It focuses on drugs that address chronic or complex diseases, where patients often need long-term treatment. That gives the company a business model centered on patented products, clinical research, and close ties to the pharmaceutical supply chain.
